However, compared with other cancers, pancreatic cancer has a unique TIME, which presents challenges for immunotherapy, and this may be one of the reasons why programmed death (PD-1)/PD ligand 1 (PD-L1) therapy is not highly sensitive to pancreatic cancer. This evidence concerns the gene CD274 and familial pancreatic carcinoma.